x

Posted 25 July, 2023

Semler Scientific, Inc. appointed Douglas Murphy-Chutorian M.D. as new CEO

Nasdaq:SMLR appointed new Chief Executive Officer Douglas Murphy-Chutorian M.D. in a 8-K filed on 25 July, 2023.


  As previously announced, on April 27, 2023, the board of directors, or Board, of Semler Scientific, Inc., or Semler, appointed Douglas Murphy-Chutorian M.D., current Class III director as interim chief executive officer and president with immediate effect.  

Don't how to trade CEO change? Read Reasons for CEO Turnover and Effect on Stock Performance.
Overview of Semler Scientific, Inc.
Health Care/Life Sciences • Medical Equipment/Supplies
Semler Scientific, Inc. engages in the provision of technology and software solutions to improve the clinical effectiveness of healthcare providers. Its multi-test service platform, WellChec, comprehensively evaluates its customers’ patients for chronic disease, including heart attacks and strokes, using its QuantaFlo product as well as other tests. The company was founded by Herbert J. Semler, Guinasso Cindy and Shirley L. Semler on August 9, 2007 and is headquartered in Santa Clara, CA.
Market Cap
$336M
View Company Details
Semler Scientific, Inc. by TradingView
Relevant filing section
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously announced, on April 27, 2023, the board of directors, or Board, of Semler Scientific, Inc., or Semler, appointed Douglas Murphy-Chutorian M.D., current Class III director as interim chief executive officer and president with immediate effect.



As contemplated by such prior disclosures, on May 25, 2023, Semler and Dr. Murphy-Chutorian entered into an 

an interim employment agreement providing for compensation and benefits consistent with his new role as interim chief executive officer. Under such agreement. Dr. Murphy-Chutorian will provide services on an-at-will basis and is eligible to receive annual base salary of $450,000 and quarterly target bonus of $100,000 per quarter based on (for 2023) achieving increased revenue ($50,000) as compared to the prior year period and achieving profitably before taxes ($50,000) for the applicable quarter. Dr. Murphy-Chutorian remains eligible to continue to receive equity grants under Semler's equity compensation plans and benefits on the same terms as other employees (including payment of life insurance policy, medical license fees and telecommunications charges). Dr. Murphy-Chutorian is already party to Semler's standard form indemnification agreement. 



As contemplated by the prior disclosures, Dr. Murphy-Chutorian's interim employment agreement suspended severance payments under his previously disclosed separation and release agreement dated April 1, 2023 unless and until his employment terminates and he signs a supplemental release, for which he will be paid $100. It was also clarified that the previously agreed severance will be paid to Dr. Murphy-Chutorian's spouse in the event termination of employment is due to his death. Semler also agreed to reimburse up to $37,500 of documented out-of-pocket legal fees and legal expenses incurred in connection with negotiating and execution of the interim employment agreement and the separation and release agreement.



Semler intends to file a copy of Dr. Murphy-Chutorian's interim employment agreement as an exhibit to its Quarterly Report on Form 10-Q for the three months ended June 30, 2023.